Table 3.
Ratio of observed (O) to expected (E) cases of new solid cancers among recipients of allogeneic HCT using high-dose Bu-Cy conditioning for AML in CR1 and CML in CP1 by diagnosis and age at transplantation
| Cancer site | Diagnosis |
Age at transplantation |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AML (N = 1742) |
CML (N = 2576) |
< 35 y (N = 2264) |
35-50 y (N = 1685) |
> 50 y (N = 369) |
||||||
| O | O/E | O | O/E | O | O/E | O | O/E | O | O/E | |
| All sites | 22 | 1.61* | 44 | 1.31 | 13 | 1.73 | 33 | 1.23 | 20 | 1.57 |
| Lip | 0 | 0 | 4 | 36.58† | 1 | 36.63 | 3 | 36.00† | 0 | 0 |
| Tongue | 1 | 8.83 | 3 | 9.42* | 1 | 19.20 | 2 | 7.36 | 1 | 9.26 |
| Mouth | 1 | 9.48 | 2 | 6.59 | 0 | 0 | 2 | 7.82 | 1 | 9.39 |
| Hypopharynx | 1 | 21.86 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 18.68 |
| Esophagus | 2 | 14.14* | 4 | 9.32† | 1 | 25.86 | 3 | 8.71* | 2 | 10.66* |
| Colon | 1 | 1.44 | 2 | 1.08 | 1 | 4.29 | 2 | 1.38 | 0 | 0 |
| Bronchus and lung | 7 | 6.32† | 4 | 1.28 | 1 | 4.60 | 5 | 2.15 | 5 | 2.95 |
| Melanoma, skin | 2 | 2.17 | 2 | 1.01 | 2 | 2.78 | 2 | 1.22 | 0 | 0 |
| Soft tissue | 2 | 14.73* | 1 | 3.54 | 3 | 20.88† | 0 | 0 | 0 | 0 |
| Breast | 0 | 0 | 9 | 1.44 | 0 | 0 | 3 | 0.49 | 6 | 3.52* |
| Uterine cervix | 1 | 2.48 | 2 | 2.25 | 1 | 2.21 | 2 | 2.68 | 0 | 0 |
| Prostate | 0 | 0 | 2 | 0.66 | 0 | 0 | 0 | 0 | 2 | 0.91 |
| Testis | 0 | 0 | 1 | 1.72 | 1 | 1.75 | 0 | 0 | 0 | 0 |
| Kidney | 0 | 0 | 1 | 1.03 | 0 | 0 | 1 | 1.25 | 0 | 0 |
| Bladder | 0 | 0 | 1 | 1.06 | 0 | 0 | 1 | 1.47 | 0 | 0 |
| Brain and nervous system | 1 | 2.87 | 3 | 4.19 | 0 | 0 | 2 | 3.72 | 2 | 10.70* |
| Adrenal gland | 0 | 0 | 1 | 37.84 | 0 | 0 | 1 | 46.15 | 0 | 0 |
| Other, unspecified‡ | 3 | 9.97† | 2 | 2.42 | 1 | 6.48 | 4 | 6.13* | 0 | 0 |
*
P ≤ .05.
†
P ≤ .01.
‡
Includes metastatic adenocarcinoma, unknown primary site (N = 2), metastatic squamous cell carcinoma, unknown primary site (N = 2), and metastatic round cell tumor, unknown primary site (N = 1).